This article was originally published in The Gray Sheet
Blood coagulation and hemostasis monitoring firm expects to introduce the InRatio coagulation monitoring system to the U.S. market in mid-2000. The firm holds several patents for its PT testing technology and plans to file for regulatory clearance in the U.S. and Europe later this year. The device will provide PT measurements at home or in the doctor's office from a fingerstick sample. The worldwide coagulations testing market is expected to exceed $500 mil. by 2004
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.